2197 — Clover Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- HK$441.00m
- -HK$22.88m
- CNY39.26m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 39.3 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 24.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 38.3 | 911 | 6,008 | 2,446 | 159 |
Operating Profit | -38.3 | -911 | -6,008 | -2,446 | -120 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -48.6 | -913 | -6,016 | -2,452 | -139 |
Provision for Income Taxes | |||||
Net Income After Taxes | -48.6 | -913 | -6,016 | -2,452 | -139 |
Net Income Before Extraordinary Items | |||||
Net Income | -48.6 | -913 | -6,016 | -2,452 | -139 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -48.6 | -913 | -6,016 | -2,452 | -139 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.042 | -0.785 | -12.9 | -2.2 | -2.14 |